Prior parameters μa = -2.2, σa = 0.75 was chosen to reflect prior knowledge that approximately 10% of Phase I compounds become approved [18] and prior standard deviations σb = 2, and σg = 2 were chosen prior belief that observed effect sizes should be moderate. Note α, for which we have chosen a nonzero mean prior, controls the baseline approval probability, not the effect of genetic evidence. Continuous covariates in X were standardized to have mean 0 and standard deviation 1 as was EC.
